Cargando…
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
Following the clinical success of cancer immunotherapies such as immune checkpoint inhibitors blocking B7/CTLA-4 or PD-1/PD-L1 signaling and ongoing numerous combination therapies in the clinic,3 bispecific antibodies (BsAbs) are now emerging as a growing class of immunotherapies with the potential...
Autores principales: | You, Gihoon, Won, Jonghwa, Lee, Yangsoon, Moon, Dain, Park, Yunji, Lee, Sang Hoon, Lee, Seung-Woo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310217/ https://www.ncbi.nlm.nih.gov/pubmed/34358141 http://dx.doi.org/10.3390/vaccines9070724 |
Ejemplares similares
-
Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
por: Moon, Dain, et al.
Publicado: (2022) -
B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8(+) tumor-infiltrating lymphocytes
por: You, Gihoon, et al.
Publicado: (2021) -
The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies
por: Yang, Chang, et al.
Publicado: (2021) -
Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
por: Blanco, Belén, et al.
Publicado: (2021) -
Hybrid Fc‐fused interleukin‐7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy
por: Kim, Ji‐Hae, et al.
Publicado: (2020)